Delhi has less than a day’s stock of Covaxin for 45-plus age group: Atishi

By: |
May 17, 2021 6:42 PM

While issuing the vaccination bulletin, Atishi said that Delhi also started walk-in vaccinations for 45-plus, healthcare workers and frontline workers from Monday.

Last week Brazil's health regulator Agência Nacional de Vigilância Sanitária (Anvisa) finally gave its approval for importing Bharat Biotech’s developed Covaxin vaccine.Last week Brazil's health regulator Agência Nacional de Vigilância Sanitária (Anvisa) finally gave its approval for importing Bharat Biotech’s developed Covaxin vaccine.

AAP MLA Atishi said on Monday that Delhi has less than a day’s stock of Covaxin left for the 45 plus age group and they will have to temporarily shut down centres administering it. The centres administering Covaxin to the 18-44 age group have been closed.

While issuing the vaccination bulletin, Atishi said that Delhi also started walk-in vaccinations for 45-plus, healthcare workers and frontline workers from Monday.

There are many people who don’t have smartphones and can’t register online, she said, adding that there were 97 schools where such centres have been opened.

“We will have five days stock of Covishield, but less than a day’s stock of Covaxin for 45 plus age group after today’s vaccination,” she said.

Atishi said they have only four days of Covishield left for the 18-44 age group. “We urge the Centre to supply us vaccines for the 18-44 age group since the new strain of coronavirus is affecting the young people,” she said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Passengers in for a tough time as PCR tests made mandatory before exiting airports
2EXCLUSIVE: Optum India MD Ritesh Talpatra on making healthcare affordable and leveraging technology
3Serum Institute seeks DCGI’s approval for Covishield as booster dose